PANEM Plans 188-Person Enzyme Trial After Stomach Removal
PANEM’s randomized, blinded design supports a future comparison, but its protocol cannot establish whether digestive enzymes improve physical quality of life after gastrectomy.
PANEM’s trial protocol does not establish whether digestive enzymes—substances that help break down food—improve physical quality of life after stomach removal. It describes a planned 188-person comparison, with no comparative treatment outcomes reported.
Evidence
The PANEM digestive-enzyme trial briefing examines one study protocol involving adults after partial or total gastrectomy, meaning surgery to remove part or all of the stomach.
The protocol plans to randomly assign 188 adults in equal proportions to digestive enzymes or placebo for six months. It is a multicenter, phase III superiority trial, designed to test whether enzymes outperform placebo. The groups receive their assigned treatments in parallel. Double-blinding conceals treatment assignments from participants and investigators.
The primary outcome is the physical sub-score of the EORTC-QLQ-C30, a cancer-specific quality-of-life questionnaire, measured at six months. Secondary outcomes include weight loss, supplemental nutrition, and laboratory measurements related to malnutrition and metabolism.
The sample-size calculation targets 80% statistical power: an 80% chance of detecting the effect assumed in the calculation if that effect exists. It uses a two-sided 5% significance threshold, testing for differences in either direction, and allows for 10% loss to follow-up. These numbers describe the design, not observed treatment effects.
Analysis
Interpretation: Random assignment, placebo control and concealed treatment assignments can reduce bias in a future comparison. Those safeguards make PANEM a structured test of an unresolved question; they do not themselves demonstrate benefit.
The nutrition measurements could help establish whether any difference in physical quality of life is accompanied by differences in weight loss, supplemental nutrition or laboratory measures. That is a question for the eventual results, not a connection already demonstrated. This is a single-study protocol report, without cross-study corroboration.
Limitations
No treatment-effect estimate or confidence interval—a range expressing statistical uncertainty—is reported. The direction, size and clinical importance of any effect therefore cannot be judged. Absence of results is not evidence that enzymes have no effect.
The protocol describes earlier trials as small and low quality. It also notes that a clinically important quality-of-life difference is often taken to be 10 points or half a standard deviation, a measure of how widely scores vary, across cancers. These are contextual benchmarks, not observed PANEM benefits; the available information does not establish their applicability specifically after gastrectomy.
What to watch
Comparative results should show how many participants completed follow-up and whether outcomes differ after partial versus total stomach removal. Weight loss and supplemental-nutrition results would help interpret any physical quality-of-life difference.
The result that would change confidence is the enzyme-versus-placebo difference in the six-month physical quality-of-life score, reported with its confidence interval and assessed against a justified threshold for a meaningful change after gastrectomy.